-
Drug sampling in many places failed!
Time of Update: 2022-05-13
At present, the Hubei Provincial Drug Administration has instructed relevant departments to take necessary control measures such as sealing up, detaining, suspending sales, and recalling drugs that do not meet the requirements, and investigate and punish the production enterprises and sampled units in accordance with relevant laws and regulations .
-
The National Health and Medical Commission issued a document: 13,000 private hospitals will be inspected
Time of Update: 2022-05-13
Inspection focus: from qualification to epidemic prevention and control According to the documents released by the National Health and Health Commission, the inspection content includes four aspects: institutional setup, standardized practice, operation management, and epidemic prevention and control, covering 15 items including hospital naming, personnel qualifications, and normalized epidemic prevention and control measures .
-
Publish documents in multiple places to dynamically adjust the "dual-channel" management catalog of medical insurance
Time of Update: 2022-05-13
On April 20, 2022, the Jiangsu Medical Insurance Bureau issued a document to dynamically adjust the "dual-channel" management and separate payment list according to the results of the dynamic adjustment of the National Drug List .
-
The top list of pharmaceutical companies' revenue is released!
Time of Update: 2022-05-13
AstraZeneca's revenue growth was mainly driven by last year's $39 billion acquisition of Alexion and the new crown vaccine Vaxzevria .
-
Novartis suspends production of two radioligand drugs due to potential quality issues
Time of Update: 2022-05-13
CompilenewbornNovartis announced on Thursday that it has suspended production of neuroendocrine tumor treatment Lutathera and recently FDA-approved prostate cancer treatment Pluvicto at its plants in Ivrea, Italy and Milburn, New Jersey .
Novartis halts US production of radioligand cancer therapies, citing potential quality issues2.
-
Hengrui Pharma Appoints New General Manager to Enhance Enterprise Transformation Momentum
Time of Update: 2022-05-13
On May 5, Hengrui Pharmaceutical announced that the company appointed Dai Hongbin as the general manager . This is the latest development of the adjustment of Hengrui Pharmaceutical's executive team
-
CDE: Technical Guidelines for Drug Clinical Dependence Research (Draft for Comment)
Time of Update: 2022-05-12
On April 18, CDE publicly issued a notice soliciting opinions on the "Technical Guidelines for Drug Clinical Dependence Research (Draft for Comment)" .
pdf 3 "Technical Guiding Principles for Drug Clinical Dependence Research (Draft for Comment)" Solicitation Feedback Form.
-
Accelerating the development of innovative therapies with the help of AI has become a consensus among domestic and foreign pharmaceutical companies
Time of Update: 2022-05-12
Genesis Therapeutics announced today that it has partnered with Eli Lilly and Company to leverage Genesis’ artificial intelligence (AI) drug discovery platform to discover innovative treatments for up to five targets across multiple therapeutic areas .
-
The State Pharmacopoeia Commission announced the draft standard of four pharmaceutical excipients including hydroxypropyl starch
Time of Update: 2022-05-12
Public draft of the standard draft of hydroxypropyl distarch phosphate pharmaceutical excipients 4.
Public draft of the standard draft of pregelatinized hydroxypropyl distarch phosphate pharmaceutical excipients
Public draft of the standard draft of pregelatinized hydroxypropyl distarch phosphate pharmaceutical excipients
-
Qilu leads the mouth dissolving film, CSPC attacks micelles, Hengrui attacks liposomes... Improved new drugs explode the trillion-dollar market
Time of Update: 2022-05-12
In terms of dosage form improvement, since 2010, Chinese pharmaceutical companies have preferred to change ordinary tablets to capsules, dispersible tablets, and sustained-release tablets, mostly for the sake of change, without considering its clinical value; from the situation in recent years , Improved new drugs with high technology or high patent barriers such as oral dissolving membranes, liposomes, and microspheres have become a hot market .
-
The new pharmacovigilance policy has been introduced intensively, and those who are good at it are protected from falling!
Time of Update: 2022-05-12
In terms of drug research and development , in the process of aligning with ICH, a series of supporting documents on pharmacovigilance have been intensively issued, such as the "Standards for the Evaluation and Management of Safety Information During Drug Clinical Trials (Trial)", "Standards for the Administration of Safety Update Reports During the Research and Development Period ( Trial Implementation)", "Case Safety Report E2B (R3) Regional Implementation Guidelines", etc.
-
Notice of the Center for Drug Evaluation on Further Strictly Strict the Receipt of Application Materials During the Epidemic Period
Time of Update: 2022-05-12
Those who do not comply with the relevant policies of Beijing's epidemic prevention and control, please do not handle the business on site temporarily .
-
The profit of innovative drugs has entered the black barrier area, and foreign companies have started to eat executives back?
Time of Update: 2022-05-12
What's been happening recently On April 1, Cornerstone Pharmaceuticals, an innovative anti-tumor and precision medicine company listed on the Hong Kong stock market, officially announced that Zhou You would be appointed as the general manager of Greater China and the head of the commercial department .
-
Special Offer - Product eBook/Regulations Red Book Latest Release
Time of Update: 2022-05-12
Regularly update and organize the company's product e-books It is convenient for customers to know the latest details of our products in one stop at any time The e-book contains supplier profiles, pr
-
67 major varieties of patents expire, who will be the first to imitate?
Time of Update: 2022-05-12
Table 2: (Partial) Potential Therapeutic Area/Generic Name Patent Expired Drugs Market size forecast in 2025 Source: New Drug Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center 03 Sales of sample hospitals increase year by year Compound growth rate up to 30% 1.
-
Shanghai pharmaceutical companies trapped in the epidemic: production and research and development are almost shut down, how long can they last?
Time of Update: 2022-05-12
A number of local pharmaceutical companies said that employees in their production departments have been under closed management since the end of March .
There are also many pharmaceutical companies who said that during the epidemic control period, most of their early R&D departments worked from home .
-
AstraZeneca/Daisankyo ADC therapy plans to be included in the priority review of Class 1 new drugs introduced by Jingxin Pharmaceutical to submit the marketing application
Time of Update: 2022-05-12
Breast cancer | AstraZeneca/Daiichi Sankyo ADC therapy proposed for priority review On April 24, the CDE official website announced that the marketing application of trastuzumab deruxtecan for injection is planned to be included in priority review for the indication of unresectable or metastatic HER2-positive adult breast cancer patients .
-
Qilu won the first imitation!
Time of Update: 2022-05-12
Qilu won the first imitation of tofacitinib sustained-release, Pfizer's second JAK inhibitor came Following the approval of AbbVie's JAK inhibitor upadatinib extended-release tablets in China, and two new indications have been added, another JAK inhibitor has entered the domestic market .
-
Alliance centralized procurement "speed-up and expansion" hammer!
Time of Update: 2022-05-12
. From the perspective of the key varieties promoted by the centralized procurement of various alliances, drugs have been extended from chemical drugs to traditional Chinese medicines, and the variety of medical equipment has been expanded, involving oral implants, electrophysiology and endoscopic staplers, new crown-related testing reagents and consumables, liver function Biochemical reagents, etc.
-
The small molecule targeted drug market is growing rapidly and will reach 100 billion yuan in 2025
Time of Update: 2022-05-12
In recent years, with the expansion of medical insurance coverage, the continuous enhancement of residents' ability to pay, and the support of a series of favorable medical innovation policies, small molecule drugs While the market size is expanding, more and more pharmaceutical companies are also accelerating their deployment in this field .
